<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02145351</url>
  </required_header>
  <id_info>
    <org_study_id>13-008306</org_study_id>
    <nct_id>NCT02145351</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure</brief_title>
  <acronym>RAPID-HF</acronym>
  <official_title>Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID-HF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine the impact of restoring normal heart rate response during exercise and daily&#xD;
      activity in patients with heart failure and a preserved ejection fraction (HFpEF) and&#xD;
      chronotropic incompetence (CI).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 7, 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygen consumption (VO2) at ventilatory anaerobic threshold (VAT) as measure of exercise capacity</measure>
    <time_frame>4 weeks after pacemaker activation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Daily activity assessed by average daily minutes active from pacemaker accelerometry</measure>
    <time_frame>4 weeks after pacemaker activation</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Scores on Kansas City Cardiomyopathy questionnaire (KCCQ)</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>NT-proBNP Levels</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Six minute walk test distance</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Self-reported symptoms of breathlessness and fatigue during cardiopulmonary exercise testing (Borg scores)</measure>
    <time_frame>4 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure With a Preserved Ejection Fraction</condition>
  <condition>Heart Failure, Diastolic</condition>
  <condition>Chronotropic Incompetence</condition>
  <arm_group>
    <arm_group_label>Pacing off</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pacing on</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this crossover study design, subjects will be randomized to pacing on or pacing off, and will switch to the opposite group midway through the study. They will be compared to themselves when pacing is on vs pacing off for endpoints of interest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Rate adaptive atrial pacing using a dual-chamber pacemaker</intervention_name>
    <description>The Azure XT DR is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.</description>
    <arm_group_label>Pacing on</arm_group_label>
    <other_name>Medtronic Azure XT DR MRI pacemaker model W1DR01</other_name>
    <other_name>Medtronic CapSureFix MRI model 5086</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pacemaker system will be implanted but set to Pacing Off.</intervention_name>
    <description>The identical pacing system will be implanted, but will be set to Pacing Off.</description>
    <arm_group_label>Pacing off</arm_group_label>
    <other_name>Medtronic Azure XT DR MRI model W1DR01</other_name>
    <other_name>Medtronic CapSureFix MRI model 5086</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Age &gt;18 years and able to provide informed consent to enroll in the trial, or consent&#xD;
             through a legal guardian or power of attorney.&#xD;
&#xD;
          2. Previous clinical diagnosis of HF with current NYHA Class II-III symptoms&#xD;
&#xD;
          3. At least one of the following: Hospitalization for decompensated HF, Acute treatment&#xD;
             for HF with intravenous loop diuretic or hemofiltration, Chronic treatment with a loop&#xD;
             diuretic for control of HF symptoms + left atrial enlargement on echocardiography or&#xD;
             E/e' ratio (≥14 average, ≥15 septal ) on echocardiography, Resting PCWP &gt;15 mm Hg or&#xD;
             LV end-diastolic pressure &gt;18 mmHg at catheterization for dyspnea and/or exercise&#xD;
             PCWP/LV end-diastolic pressure &gt;25 mmHg, or Elevated NT-proBNP level (≥300 pg/ml )&#xD;
&#xD;
          4. Left ventricular EF ≥40% within 12 months with clinical stability&#xD;
&#xD;
          5. Stable cardiac medical therapy for ≥30 days&#xD;
&#xD;
          6. Sinus rhythm&#xD;
&#xD;
          7. Chronotropic incompetence on recent (within 6 months) clinical or screening exercise&#xD;
             test, defined as heart rate reserve (HRR) &lt;0.80 or &lt;0.62 if on beta blockers&#xD;
&#xD;
          8. Meet both screening criteria on clinically-performed cardiopulmonary exercise testing&#xD;
             within 12 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Inability to exercise, or non-cardiac condition that precludes exercise testing&#xD;
&#xD;
          2. Any contraindication to a pacemaker system&#xD;
&#xD;
          3. Non-cardiac condition limiting life expectancy to less than one year&#xD;
&#xD;
          4. Significant left sided structural valve disease (&gt;mild stenosis, &gt;moderate&#xD;
             regurgitation)&#xD;
&#xD;
          5. Hypertrophic cardiomyopathy&#xD;
&#xD;
          6. Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)&#xD;
&#xD;
          7. Pericardial disease&#xD;
&#xD;
          8. Non-group 2 pulmonary arterial hypertension&#xD;
&#xD;
          9. Chronic stable exertional angina&#xD;
&#xD;
         10. Acute coronary syndrome or revascularization within 60 days&#xD;
&#xD;
         11. Other clinically important causes of dyspnea&#xD;
&#xD;
         12. Atrial fibrillation&#xD;
&#xD;
         13. PR interval &gt;210 msec&#xD;
&#xD;
         14. Resting heart rate (HR) &gt; 100 bpm&#xD;
&#xD;
         15. A history of reduced ejection fraction (EF&lt;40%)&#xD;
&#xD;
         16. Advanced chronic kidney disease (GFR &lt; 20 ml/min/1.73m2 by modified MDRD equation)&#xD;
&#xD;
         17. Women of child bearing potential without negative pregnancy test and effective&#xD;
             contraception&#xD;
&#xD;
         18. Severe anemia (Hemoglobin &lt;10 g/dL)&#xD;
&#xD;
         19. Severe hepatic disease&#xD;
&#xD;
         20. Complex congenital heart disease&#xD;
&#xD;
         21. Listed for cardiac transplantation&#xD;
&#xD;
         22. Other class I indications for pacing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Borlaug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Verbout-Kveene, CRC</last_name>
    <phone>507-255-2200</phone>
    <email>Kveene.Laura@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Verbout-Kveene</last_name>
      <phone>507-255-2200</phone>
      <email>Kveene.Laura@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Borlaug</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret Redfield</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Barry Borlaug</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>HFpEF</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Heart failure with preserved ejection fraction</keyword>
  <keyword>Chronotropic incompetence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

